Basic information Safety Supplier Related
ChemicalBook >  Product Catalog >  Pharmaceutical intermediates >  Bulk Drug Intermediates >  4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid

Basic information Safety Supplier Related

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid Basic information

Product Name:
4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid
Synonyms:
  • 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid
  • 4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzoic acid
  • Fluralaner Impurity 2
  • Fluralaner Impurity 3
  • Fluralaner-024
  • Fluralaner Impurity 6
  • Fluralaner N-1 intermediate
  • Benzoic acid, 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-3-isoxazolyl]-2-methyl-
CAS:
864725-62-2
MF:
C18H12Cl2F3NO3
MW:
418.19
Product Categories:
  • API
Mol File:
864725-62-2.mol
More
Less

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid Chemical Properties

Boiling point:
511.3±60.0 °C(Predicted)
Density 
1.49±0.1 g/cm3(Predicted)
storage temp. 
2-8°C Refrigerator
pka
3.61±0.25(Predicted)
More
Less

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid Usage And Synthesis

Uses

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid is an organic intermediate compound used in the synthesis of Fluralaner.

Synthesis

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acid is prepared by the reaction of 2-methyl-4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-benzoic acid and 3-bromo-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazole. The steps are as follows:
In a 100 mL three-necked flask, under nitrogen protection, add 3-bromo-5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazole (700 mg, 1.93 mmoL), 2-methyl-4-(4,4,5,5-tetramethyl-1,3-dioxaborolan-2-yl)benzoic acid (560 mg, 2.14 mmoL), potassium acetate (379 mg, 3.86mmol), 1,4-dioxane (15mL), water (1.5mL) and Pd(dppf)Cl2 (141mg, 0.19mmol), incubate the reaction at 85±5 for 8h, stop heating to room temperature, then Water (50 mL) was added to quench and then extracted with dichloromethane (45 mL×2), the organic phases were combined, the organic phase was washed once with saturated brine (50 mL), and then the organic phase was washed with anhydrous sodium sulfate (10.0 g). ) was dried for 2 h, the organic phase was concentrated to dryness under reduced pressure, and the concentrated residue was purified by silica gel column chromatography (developing solvent: n-heptane/ethyl acetate=10:1-3:1) to obtain 4-(5-(3 ,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-2-methylbenzoic acid (694 mg, 86%) as a pale yellow solid.

4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methylbenzoic acidSupplier

Madision Biomedical Co., Ltd. Gold
Tel
028-87439248 19150327610
Email
553691721@qq.com
Jinan Hongda Trading Co., Ltd. Gold
Tel
18596078578 18265506873
Email
kongjiangsd@163.com
Henan Dongyao Pharmaceutical Technology Co., Ltd Gold
Tel
18519331287
Email
1751713684@qq.com
Jinan Chenghui Shuangda biological Co., LTD Gold
Tel
0531-58897003 15550412551
Email
market@jnchsd.com
Changzhou Yuanhe Biopharmaceutical Co., Ltd Gold
Tel
15995091686
Email
15995091686@163.com